Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer.

ABSTRACT:

Objective

To review the evidence for the use of bisphosphonates to reduce skeletal morbidity in cancer patients with bone metastases.

Data sources

Electronic databases, scanning reference lists, and consultation with experts and pharmaceutical companies. Foreign language papers were included.

Study selection

Included trials were randomised controlled trials of patients with malignant disease and bone metastases who were treated with oral or intravenous bisphosphonate compared with another bisphosphonate, placebo, or standard care. All trials measured at least one outcome of skeletal morbidity.

Results

95 articles were identified; 30 studies fulfilled inclusion criteria. In studies that lasted > or = 6 months, compared with placebo bisphosphonates significantly

SUBMITTER: Ross JR 

PROVIDER: S-EPMC188427 | biostudies-literature | 2003 Aug

REPOSITORIES: biostudies-literature